The Epidemiology of COVID-19 Vaccine-Induced Myocarditis

Table 2

Overview of the baseline characteristics of the studies.

Reference	Publication year	Country	Type of study	Mean age (years)	Sample size	Follow-up (days)	Male (% total)	mRNA vaccine type	Number of myocarditis cases	Male (% myocarditis)	Myocarditis diagnostics	Number of hospitalizations	Number of deaths
El Sahly et al. [49]	2021	USA	Population study	51	14287	14	53	Moderna	0	0	N/A	0	0
Walter et al. [50]	2022		Population study	8	1518	7	52	Pfizer	0	0	N/A	0	0
Simone et al. [51]	2021		Population study	49	2392924	10	46	Pfizer/Moderna	15	100	Clinical	0	0
Ali et al. [52]	2021		Population study	14	2489	83	52	Moderna	1	0	N/A	0	0
Diaz et al. [53]	2022		Population study	57	2000287	N/A	41	Pfizer/Moderna	20	75	Abnormal troponin or CMR evidence	19	0
Montgomery et al. [54]	2021		Population study	25	2810000	N/A	100	Pfizer/Moderna	23	100	Clinical	0	0
Le Vu et al. [55]	2022	France	Population study	28	18129	30	61	Pfizer/Moderna	82	79	Hospital admission codes	N/A	N/A
Husby et al. [56]	2022	Denmark	Population study	N/A	3482295	28	N/A	Pfizer	48	73	Clinical diagnosis + troponin elevation + hospitalization >24 hours	28	1
			Population study	N/A	498814	28	N/A	Moderna	21	N/A	Clinical diagnosis + troponin elevation + hospitalization >24 hours	8	0
Patone et al. [57]	2022	UK	Population study	56	16993389	28	33	Pfizer	158	67	Hospital admission codes	N/A	N/A
			Population study	40	1006191	28	26	Moderna	9	83	Hospital admission codes	N/A	N/A
Witberg et al. [58]	2021	Israel	Population study	44	2500000	42	49	Pfizer	54	94	Clinical	1	1
Mevorach et al. [59]	2021		Population study	33	5000000	30	49	Pfizer	136	91	Clinical	114	1
Barda et al. [46]	2021		Population study	38	884828	42	52	Pfizer	21	91	Clinical	N/A	N/A